Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.

Svenja Petersohn Gilles Andre Salles Michael L Wang James Wu Sally W Wade Claire L Simons Craig Bennison Rubina SiddiqiWeimin PengIoana KloosGab Castaigne Georg Hess

Published in: Journal of medical economics (2022)

Considering the survival and quality of life benefits compared to SoC, KTE-X19 for R/R MCL appears as a cost-effective treatment in the real-world UK setting.

Keyphrases

healthcare
acute lymphoblastic leukemia
acute myeloid leukemia
palliative care
diffuse large b cell lymphoma
multiple myeloma
quality improvement
hodgkin lymphoma
cross sectional
pain management
free survival
bone marrow
chronic pain
cell therapy